HMGB3 and ovarian carcinoma: To investigate whether the MAPK/ERK signaling pathway is required for HMGB3-mediated proliferation and mobility of ovarian cancer, we used two specific MAPK signaling pathway inhibitors, AZD6244 and PD0325901, to suppress MAPK/ERK activity.